Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 booster study of DS-5670 bivalent and related SARS-CoV-2 vaccines versus Comirnaty in participants aged 12 years and older
jRCT2071220111Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of DS-5670a + DS-5670b, DS-5670a and tozinameran in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 Omicron BA.5 and Seroresponse rate against SARS-CoV-2 Omicron BA.5. Started May 2023; status: completed.
02
Drugs
DS-5670a + DS-5670bDS-5670atozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071220111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220111.